Reverse cholesterol transport and hepatic osteodystrophy

Research output: Contribution to journalComment/debate


In this issue of Cell Metabolism, Lu et al. show that chronic liver disease increases the expression and activity of PP2Ac, a phosphatase that downregulates the excretion of lecithin-cholesterol aceyltransferase (LCAT). LCAT, a liver-derived enzyme, protects bone and prevents bone loss, and its lowered levels in progressive liver injury cause hepatic osteodystrophy (HOD) and worsen liver fibrosis. These discoveries open the possibility that recombinant LCAT may be a treatment for both HOD and liver fibrosis.

Original languageEnglish
Pages (from-to)347-349
Number of pages3
JournalCell Metabolism
Issue number3
StatePublished - 1 Mar 2022


Dive into the research topics of 'Reverse cholesterol transport and hepatic osteodystrophy'. Together they form a unique fingerprint.

Cite this